Omeros (OMER) Misses Q1 EPS by 19c

Omeros (NASDAQ: OMER) reported Q1 EPS of ($0.62), $0.19 worse than the analyst estimate of ($0.43).

“During the first quarter of 2018, we made tremendous progress in our MASP-2 program,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “We believe that we now have clear paths to accelerated approval for OMS721 in both stem-cell TMA and IgA nephropathy. With breakthrough therapy designations in both of these indications, we look forward to continuing to work closely with FDA and, for stem-cell TMA, we have initiated preparations for a BLA submission. Our PDE7 inhibitor OMS527 is poised to enter the clinic in mid-year and, in late 2019 through 2020, we expect to begin clinical trials for our MASP-3 antibody OMS906 and for our small-molecule MASP-2 inhibitors. A number of our GPCR programs are also moving toward the clinic, providing the potential for wholly new mechanisms for the treatment of a broad range of diseases and disorders, including cancers. With the Omeros team and the reinstatement of CMS separate payment for OMIDRIA, we believe that we will have the resources to deliver on the immense promise of these programs to benefit patients, many of whom have conditions for which there are no treatments.”

For earnings history and earnings-related data on Omeros (OMER) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
• Accenture downgraded by TD Cowen on AI concerns